Clinical Trial Search

Primary: Change in Physical Dimensions in Health Status of Elderly Patients From 4 Weeks Pre Operatively to 9 Months Post Operatively After THR. Health Status is Measured by the…

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts — 0; 0; 1; 0 participants

Primary: Maximum Plasma FVIII Activity (Cmax) — 1.147 IU/milliliter (mL)

Primary: Number of Participants That Successfully Completed the 1-year Intervention

Primary: Maximum Observed Plasma Concentration (Cmax) (Single Dose) — 1.920; 3.830 nanograms per milliliter (ng/mL)

Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage

Primary: Cmax of Faldaprevir (BI 201335) — 3520; NA; 8780; 9950 ng/mL — p=1.0000

Primary: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12 — 358.9; 353.1; 17.7…

Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants

Primary: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-infinity). — 191; 192; 179; 191 h*ng/mL

Primary: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours After the Single Infusion of BCD-055/Remicade — 26282582; 25914888 (ng/ml)*hour

Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1 — 37.54 h*μg/mL

Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…

Primary: Adverse Events — 6; 2; 1; 0 participants

Primary: Virologic Response (VR) — 14.3; 22.2; 55.6; 88.9 percentage of participants